Publications

Add filters (0)

164 results

Molecular signatures discriminating different types of rejection in human liver transplants.

December 1, 2025

J Hepatol

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Read publication

Molecular signatures discriminating different types of rejection in human liver transplants.

December 1, 2025

J Hepatol

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Read publication

Molecular signatures discriminating different types of rejection in human liver transplants.

December 1, 2025

J Hepatol

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Read publication

Molecular signatures discriminating different types of rejection in human liver transplants.

December 1, 2025

J Hepatol

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Read publication

Molecular signatures discriminating different types of rejection in human liver transplants.

December 1, 2025

J Hepatol

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Read publication

Molecular signatures discriminating different types of rejection in human liver transplants.

December 1, 2025

J Hepatol

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Read publication

Molecular signatures discriminating different types of rejection in human liver transplants.

December 1, 2025

J Hepatol

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication